Back to Search
JENNIFER KILLION, M.D.
M.D.
Internal Medicine Physician
NPI: 1649269648IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
35026(IA)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
UNIVERSITY OF IOWA, RJ & L CARVER COLLEGE OF MEDICINE
Class of 2000
Research & Publications (17)
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
PMID 15205332·Cancer Res·2004
7-preclinical
Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines.
PMID 15047217·Gynecol Oncol·2004
7-preclinical
Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma.
PMID 14871965·Clin Cancer Res·2004
7-preclinical
Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
PMID 14695158·Clin Cancer Res·2003
7-preclinical
Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
PMID 12738744·Clin Cancer Res·2003
7-preclinical
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
PMID 12644539·J Natl Cancer Inst·2003
7-preclinical
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
PMID 12631626·Clin Cancer Res·2003
7-preclinical
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
PMID 12429651·Clin Cancer Res·2002
7-preclinical
Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
PMID 12384530·Cancer Res·2002
7-preclinical
Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report.
PMID 12162763·Arch Otolaryngol Head Neck Surg·2002
7-preclinical
Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
PMID 12114447·Clin Cancer Res·2002
7-preclinical
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
PMID 11776753·Cancer Biother Radiopharm·2001
4-observational
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
PMID 11489840·Clin Cancer Res·2001
7-preclinical
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
PMID 10741721·Clin Cancer Res·2000
7-preclinical
Differential regulation of type IV collagenases and metalloelastase in murine macrophages by the synthetic bacterial lipopeptide JBT 3002.
PMID 10727754·Int J Immunopharmacol·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1215 DUFF AVE
AMES, IA 50010 - Phone
- (515) 239-4431
Quick Facts
- NPI
- 1649269648
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 26
- Publications
- 17
Are you this provider?
Claim Your Profile